Aridis Pharmaceuticals Inc. (ARDS) News

Aridis Pharmaceuticals Inc. (ARDS): $3.87

0.13 (+3.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ARDS News Items

ARDS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ARDS News From Around the Web

Below are the latest news stories about Aridis Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARDS as an investment opportunity.

Aridis Pharmaceuticals Announces Second Quarter 2021 Results

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2021.

Yahoo | August 12, 2021

Analysts Estimate ARIDIS PHARMACT (ARDS) to Report a Decline in Earnings: What to Look Out for

ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | August 3, 2021

Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,947,556 shares of the Company's common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 2,473,778 shares of the Company's common

Yahoo | August 2, 2021

Aridis Pharmaceuticals'' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)

LOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that animal efficacy data reported by

PR Newswire | July 26, 2021

Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that animal efficacy data reported by the Coronavirus Immunotherapeutics Consortium (CoVIC) showed that the Company's COVID-19 monoclonal antibody (mAb) AR-711, one of two mAbs in the AR-712 cocktail, ranks among the top 5 most potent mAbs that the CoVIC consortium have studied to date.

Yahoo | July 26, 2021

Aridis Acquires Rights For Development And Commercialization Of Suvratoxumab

LONDON (dpa-AFX) - Aridis Pharmaceuticals Inc. (ARDS) said that it has acquired global exclusive rights from AstraZeneca (AZN, AZN.L) for development and commercialization of the late stage monocl

FinanzNachrichten | July 19, 2021

Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to in-license the late stage monoclonal antibody candidate, suvratoxumab.

Yahoo | July 19, 2021

Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant

Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.

Yahoo | July 13, 2021

Aridis Pharma's COVID-19 Antibody Neutralizes Delta Variant In Animal Model

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has announced that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant of COVID-19 at a highly effective level (~20ng/mL). Binding analyses project that AR-712 will be effective against all variants on the U.S. CDC's variants of interest and concern lists. The dual antibody cocktail will be delivered as an inhaled treatment and is expected to provide broad coverage of all known high-risk variants. In addition, Aridis announced precli

Yahoo | July 13, 2021

Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant

LOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that its COVID-19 mAb cocktail AR-712

PR Newswire | July 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8605 seconds.